Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age. This condition is associated with various hormonal, reproductive, and metabolic alterations, including androgen excess, ovulatory disorders, and a hyperinsulinemic state. A personalized therapeutic approach is necessary to improve PCOS, focusing on patient's main concerns, with the goal of addressing ovarian dysfunction, reducing hyperandrogenism, and improving metabolic alterations, particularly through weight reduction. The therapeutic class of glucagon-like peptide 1 receptor analogues (GLP-1 RA) represents an attractive option for PCOS due to its various beneficial effects, such as weight loss. In this review, we discuss the clinical and pathological aspects of PCOS, as well as the data and potential role of GLP-1 RA in managing this condition.